ZYRAYDI
LIVE

Serial Number

97319656

Owner

Zelira Therapeutics Limited

Attorney

Elizabeth M. O'Donoghue

Filing Date

Mar 18, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ZYRAYDI Trademark

Serial Number: 97319656

ZYRAYDI is a trademark filed by Zelira Therapeutics Limited on March 18, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Zelira Therapeutics Limited (8 trademarks)

Level 26, 140 St Georges Terrace
Perth WA6000 , AU

Entity Type: 99

Trademark Details

Filing Date

March 18, 2022

Registration Date

Not Registered

Published for Opposition

November 25, 2025

Goods & Services

Non-prescription medicines, namely, pills, tablets, capsules, caplets, and pharmaceutical preparations for the treatment and prevention of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological, immune system related diseases and disorders, Parkinson's disease, insomnia, diabetic neuropathy, Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; medical and pharmaceutical preparations for the treatment and prevention of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological, immune system related diseases and disorders, Parkinson's disease, insomnia, diabetic neuropathy, Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome

Filing History

NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 20, 2026 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 25, 2025 NPUB
PUBLISHED FOR OPPOSITION
Nov 25, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 19, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 23, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 22, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 22, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 22, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Feb 27, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Feb 27, 2024 XELR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Feb 27, 2024 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 27, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 27, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 27, 2024 REAP
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 1, 2023 GNRN
NON-FINAL ACTION E-MAILED
Dec 1, 2023 GNRT
NON-FINAL ACTION WRITTEN
Dec 1, 2023 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 31, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 31, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 31, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 2, 2023 GNRN
NON-FINAL ACTION E-MAILED
Aug 2, 2023 GNRT
NON-FINAL ACTION WRITTEN
Aug 2, 2023 CNRT
ASSIGNED TO EXAMINER
Jul 24, 2023 DOCK
ASSIGNED TO EXAMINER
Jan 5, 2023 DOCK
ASSIGNED TO EXAMINER
Dec 29, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 23, 2022 NWOS
NEW APPLICATION ENTERED
Mar 22, 2022 NWAP